Mark Cuban

Mark Cuban × Julie Yoo × Erik Torenberg

Cost Plus Drugs grew from 111 generics in January 2022 to roughly 4,000 SKUs at a fixed 15% markup, with its public API giving buyers a price benchmark.Pre-signing AI review of Dallas’s 1,335-page PBM contract could uncover overcharges; savings may reach millions for organizations above 1,500 employees or members, depending on existing overcharging.Manufacturing pods target roughly 200 annual sales within two years, though 1,000 ANDA applications alone would cost $365 million plus other fees, before manufacturing investment.

Mark Cuban × Steven Bartlett

Cuban sees bubble-like pricing in Bitcoin, Micron, Google and Apple, where a one-cent earnings difference can coincide with an 18% share-price move, though he cannot identify a crash trigger.He questions whether AI financing needs will outrun returns as hyperscalers compete with government borrowers, and what gets crowded out if 10-year yields rise.He advocates patience and cash for a potential downturn, while timing, trigger and eventual winners remain unknown.

Mark Cuban × Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

The AI bubble’s likely casualties are VCs, funds, and PE firms concentrated in peak-priced private rounds, while infrastructure spending depends on whether token economics and video demand justify today’s buildout.Enterprise implementation remains the bottleneck as agents drift and require forward-deployed talent, but falling build costs are opening bespoke software and IPO-funded acquisition strategies for smaller AI companies.

Erik Torenberg × Mark Cuban

Cuban’s clearest business thesis pairs transparent pricing and AI-native operators with broad employee equity, arguing that ESOP workers earn dramatically more and turn over less while small firms gain immediate productivity tools.He would replace opaque insurers and PBMs with patient shopping, catastrophic reinsurance, and government-guaranteed financing, while NBA media rights and second-apron constraints make subscription growth and patient team-building the next tests.

Mark Cuban × Tucker Carlson

Cost Plus Drugs exposes extreme pricing gaps by publishing drug costs, adding 15%, and charging $5 each for shipping and pharmacist review, with customers reporting $21 bills instead of $900-$2,000 quotes.PBM formularies control access for more than 180 million people and can block manufacturers from supplying Cost Plus, while the ACA subsidy cliff could raise premiums for 12.5 million people, making transparency, reform, and political execution key risks to monitor.